Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Fineline Cube Jul 1, 2026
Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Fineline Cube Jul 1, 2026
Company

EQRx Accelerates US Development of Two Chinese-Licensed Cancer Drugs

Fineline Cube Aug 15, 2022

US-based pharma EQRx Inc. (Nasdaq: EQRX) has revealed its latest plans to accelerate the US...

Company

Novartis Aims for China to Be Second – Largest Market by 2024

Fineline Cube Aug 15, 2022

Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...

Company Deals R&D

ESR Group Enters Life Sciences with Zhangjiang NEO Acquisition

Fineline Cube Aug 15, 2022

Hong Kong-based real estate asset manager ESR Group Ltd (HKG: 1821) has made its first...

Company Deals Digital

ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China

Fineline Cube Aug 15, 2022

Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with...

Company Deals

E-Health Now Raises Funds for Oncology and Cardiovascular Digital Health Products

Fineline Cube Aug 15, 2022

E-Health Now, a Beijing-based commercial insurance-focused health management service solutions provider, has raised an undisclosed...

Company Deals Digital Hospital

KingYee and XINSEC IOT Form Strategic Partnership for Smart Ward Solutions

Fineline Cube Aug 15, 2022

Shanghai-based KingYee, a leading domestic intelligent medical technology and service provider, has entered into a...

Company Drug

Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China

Fineline Cube Aug 15, 2022

China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed...

Company Deals

Bennu Biotherapeutics Raises Over RMB100m in Angel+ Round for Global Pipeline Development

Fineline Cube Aug 15, 2022

Shanghai-based cell therapy specialist Bennu Biotherapeutics has raised over RMB100 million (USD14.8 million) in an...

Company Drug

Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study

Fineline Cube Aug 15, 2022

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Company Drug

Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer

Fineline Cube Aug 15, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application...

Company

Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact

Fineline Cube Aug 12, 2022

Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022...

R&D

Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients

Fineline Cube Aug 12, 2022

A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted...

Company Deals

Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem

Fineline Cube Aug 12, 2022

Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson &...

Company Deals

Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech

Fineline Cube Aug 12, 2022

Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a...

Company Deals

WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production

Fineline Cube Aug 12, 2022

WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...

Company Deals

Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board

Fineline Cube Aug 12, 2022

Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...

Company Drug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

Fineline Cube Aug 12, 2022

InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...

Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Company Deals

BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development

Fineline Cube Aug 12, 2022

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...

Policy / Regulatory

China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties

Fineline Cube Aug 12, 2022

The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security...

Posts pagination

1 … 660 661 662 … 689

Recent updates

  • RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development
  • CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
  • Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Company Drug

CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting

Company Drug

Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.